SPCC shared a post on LinkedIn:
“We are pleased to announce that our two webinars dedicated to the evolving field of MRD in Multiple Myeloma are now available for on-demand viewing on OncoCorner.
Part 1: Foundations and Clinical Relevance Explore the biological basis of MRD and its current impact on clinical decision-making.
Part 2: Future Directions and Controversies A deep dive into emerging technologies, standardisation challenges, and the future of MRD-driven therapy.
- Free of charge
- CME Accredited
This activity is supported by: an independent grant from Cloud Pathology Group and by an unrestricted medical contribution from Sanofi (Phase 1); by an unrestricted medical contribution from Sanofi, with procedures ongoing for the finalisation of further independent support from a second company (Phase 2).”
Other articles about SPCC on OncoDaily.
